Clinical trials: Pulmonary Hypertension, Primary
Pulmonary Arterial Hypertension
Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)
The purpose of this study is to assess the safety and tolerability of sorafenib in patients with PAH already on existing therapy with a prostacyclin [epoprostenol (Flolan)], treprostinil (Remodulin), or iloprost alone, or with or…
- Trial name
- NCT00452218
- Testing
- Sorafenib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Chicago
Pulmonary Arterial Hypertension
Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH
This is a multi-center, randomized, double-blind, controlled, Phase 2 study to assess the safety, tolerability, and efficacy of pemziviptadil (PB1046) at the optimally titrated dose after 16 weeks of treatment.
- Trial name
- VIP (NCT03556020)
- Testing
- Pemziviptadil (PB1046)
- Where
- 26 sites in United States
- Volunteers
- 35 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Pulmonary Arterial Hypertension
Pilot Randomized Trial of Ambulatory Exercise in Pulmonary Hypertension
The researchers are investigating if changing an individual's behaviors may have an impact on outcomes for patients with pulmonary arterial hypertension (PAH).
- Trial name
- PaRTAkE-PH (NCT04254289)
- Testing
- Usual Care, Home-based exercise program
- Where
- United States
- Sponsor
- University of Michigan
Pulmonary Vascular Disease, Pulmonary Artery Hypertension
HA Residents With PVD, 6MWD Assessed at HA (2840m) vs LA (Sea Level)
To study the effect of relocation from 2840m (Quito) to sea level (Pedernales) in patients with pulmonary vascular diseases (PVD) defined as pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension (PH)…
- Conditions
- Pulmonary Vascular Disease, Pulmonary Artery Hypertension, Chronic Thromboembolic Pulmonary Hypertension
- Trial name
- NCT05996302
- Testing
- Relocation to sea level
- Where
- Switzerland
- Volunteers
- 24 people
- Sponsor
- University of Zurich
Coronary Artery Disease, Heart Failure
Stress Echo 2020 - The International Stress Echo Study
Background: Stress echocardiography (SE) has an established role in evidence-based guidelines, but recently the breadth and variety of applications has extended well beyond coronary artery disease (CAD).
- Conditions
- Coronary Artery Disease, Heart Failure, Hypertrophic Cardiomyopathy, Aortic Valve Disease
- Trial name
- SE2020 (NCT03049995)
- Testing
- Left ventricular contractile reserve SE, B-lines SE, Left ventricular outflow tract gradient SE
- Where
- Italy
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Fatebenefratelli Hospital
Pulmonary Arterial Hypertension
Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titration in Pulmonary Arterial Hypertension
This is an open-label, multicenter, parallel, randomized (1:1 Slow Dose Titration Group; Rapid Dose Titration Group), two-group study to evaluate the safety, tolerability, pharmacokinetics and efficacy of slow and rapid dose…
- Trial name
- NCT02893995
- Testing
- Slow Dose Titration Group of Subcutaneous Treprostinil, Rapid Dose Titration Group of Subcutaneous Treprostinil
- Where
- 10 sites in China
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension
Pulmonary Hypertension Modality of Death and Validation of REVEAL Risk Score
Pulmonary Arterial Hypertension (PAH) is a chronic disease characterized by a progressive increase in pulmonary vascular resistance (PVR), which leads to right ventricular (RV) failure, and ultimately death.
- Trial name
- ASPYRE-1 (NCT04677608)
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- iPHNET (italian Pulmonary Hypertension NETwork)
Pulmonary Arterial Hypertension
A Multi-Center, Open-Label, Multiple Dose, Dose Finding Study Exploring the Safety and Tolerability of Beraprost Sodium Modified Release in PAH Patients
This study is an international, open-label, multi-center, Phase II, multiple dose, dose-finding study to investigate the safety, tolerability and pharmacokinetic characteristics of BPS-MR tablets in male and female patients with…
- Trial name
- NCT00781885
- Testing
- Beraprost sodium modified release
- Where
- 6 sites in United States, Belgium and 1 more
- Volunteers
- 19 people
- Sponsor
- Lung Biotechnology PBC
Pulmonary Arterial Hypertension
Evaluation of Pulmonary Perfusion Heterogeneity and Compliance in Patients With Pulmonary Hypertension Using Positron Emission Tomography Imaging
The purpose of the study is to find out how the blood flow changes in the lungs of people with pulmonary hypertension compared to healthy individuals without pulmonary hypertension.
- Trial name
- NCT01461343
- Testing
- CT imaging, functional PET imaging
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Healthy Volunteers
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of BC 007 in Healthy Subjects
Berlin Cures develops BC 007 to treat patients suffering from diseases (chronic heart failure, pulmonary hypertension, chronic fatigue syndrome etc.) which are associated with functional autoantibodies (AAB) directed against…
- Trial name
- NCT02955420
- Testing
- BC 007, NaCl 0.9 %
- Where
- Germany
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Berlin Cures GmbH
Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension
Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals
Pulmonary arterial hypertension (PAH) is a severe disease with a delayed diagnosis and markedly elevated mortality. High-risk populations, such as those with known genetic defects, provide a unique opportunity to determine the…
- Conditions
- Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Unaffected Mutation Carriers: Healthy Participants With a Known BMPR2 Gene Mutation and Normal Pulmonary Pressure and RV Function on Echo, Healthy Individuals With no Cardiopulmonary Disease
- Trial name
- RARE-PAH (NCT05584722)
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Vanderbilt University Medical Center
HIV Infections, Hypertension
ENHANCE-EvideNce Led Co-created HeAlth Systems interventioNs for MLTCs CarE
The goal of this study is to determine the effect of the ENHANCE intervention in improving clinical outcomes and evaluating the effects of the intervention on implementation processes and outcomes.
- Conditions
- HIV Infections, Hypertension, Diabetes Mellitus, Asthma
- Trial name
- ENHANCE (NCT06248190)
- Testing
- ENHANCE intervention (health systems)
- Where
- 32 sites in South Africa
- Volunteers
- 1,837 people
- Sponsor
- University of KwaZulu
Scleroderma, Pulmonary Artery Hypertension
Cardiac Assessment by PV Loop in IPAH and Scleroderma PAH
This observational study is being done to understand why people with scleroderma can develop pulmonary arterial hypertension (high blood pressure in the lungs, abbreviated PAH) and a weak heart muscle (heart failure).
- Trial name
- CALIPSO (NCT04610788)
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Johns Hopkins University
Pulmonary Arterial Hypertension
A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension
The purpose of this study is to see how much study drug is in the blood of children with pulmonary arterial hypertension (PAH) after dosing to establish the correct dose for further clinical research.
- Trial name
- NCT01484431
- Testing
- Tadalafil- Tablet or Oral suspension
- Where
- 16 sites in United States, Canada and 4 more
- Volunteers
- 20 people
- Sponsor
- Eli Lilly and Company
Pulmonary Arterial Hypertension
Local Open-Label Access Study For Patients Who Completed A1481244 Study In Brazil
The purpose of this study is to provide sildenafil therapy to patients who completed the A1481244 study for the treatment of PAH, and reside in Brazilian States where Revatio™ is not supplied by Health Secretary, and are judged…
- Trial name
- NCT00866983
- Testing
- sildenafil (Revatio) 20 mg TID
- Where
- 2 sites in Brazil
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pulmonary Arterial Hypertension
A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)
The objectives of this study are to evaluate the efficacy and safety of sotatercept (MK-7962) treatment (plus background pulmonary arterial hypertension (PAH) therapy) versus placebo (plus background PAH therapy) at 24 weeks in…
- Trial name
- NCT04576988
- Testing
- Sotatercept, Background PAH Therapy
- Where
- 120 sites in United States, Argentina and 19 more
- Volunteers
- 324 people
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Pulmonary Arterial Hypertension
Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension
This study enrolls patients with pulmonary arterial hypertension (PAH) treated with inhaled treprostinil. During the study, the treatment with inhaled treprostinil will be tapered off and simultaneously replaced with an oral…
- Trial name
- TRANSIT-1 (NCT02471183)
- Testing
- Selexipag
- Where
- 15 sites in United States
- Volunteers
- 34 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension, Obstructive Sleep Apnea
Obstructive Sleep Apnea (OSA) in Pulmonary Arterial Hypertension (PAH)
The purpose of this study is to determine whether pulmonary arterial hypertension can worsen or even cause sleep apnea. It is hypothesized that if pulmonary arterial hypertension does indeed worsen or cause sleep apnea, then the…
- Trial name
- NCT01835080
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Inova Health Care Services
Pulmonary Arterial Hypertension, Insulin Resistance
Pulmonary Arterial Hypertension Improvement With Nutrition and Exercise (PHINE)
The purpose of this study is to investigate the extent to which diet and exercise may improve PAH through the modulation of insulin sensitivity.
- Trial name
- NCT03288025
- Testing
- Nutrition and Exercise
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- The Cleveland Clinic
Pulmonary Arterial Hypertension
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - PDE5
This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the…
- Trial name
- NCT05039086
- Testing
- PDE5 inhibitor, Endothelin Receptor Antagonists
- Where
- United States
- Volunteers
- 13,021 people
- Sponsor
- Brigham and Women's Hospital